# Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct05338931/  
OnCo record `nct05338931` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AT101 in hodgkin lymphoma and non-hodgkin lymphoma, run by AbClon, now recruiting.

## Summary

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05338931 by AbClon, with 82 participants planned, started 2022-03-15 and due to reach its primary completion in 2030-03-15. Interventions recorded: AT101(Anti-CD19 Chimeric Antigen Receptor T cell). Conditions listed: B-cell Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05338931
- Phase: 1/2
- Setting: An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Sponsor: AbClon
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT05338931: https://clinicaltrials.gov/study/NCT05338931

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AT101](https://onco.cc/drugs/at101/)

---
JSON: https://onco.cc/api/v1/entities/nct05338931.json